369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in s...
369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers
About this item
Full title
Author / Creator
Mahalingam, Devalingam , Mulcahy, Mary , Juric, Dejan , Patel, Manish , Pant, Shubham , Ulahannan, Susanna , Dowlati, Afshin , Bullock, Andrea , Vaickus, Lou , Fyfe, Susanne , Vincent, Melanie , Wang, Suming , Chen, Jian , Crochiere, Marsha , Watnick, Randolph , Cieslewicz, Michael and Watnick, Jing
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundOne barrier to treating pancreatic cancer is the immunosuppressive tumor microenvironment (TME). VT1021 is a cyclic peptide derived from prosaposin and stimulates thrombospondin-1 (Tsp-1) production in myeloid derived suppressor cells. Tsp-1 binds to CD36 on macrophages to convert M2 macrophages to anti-tumorigenic M1 macrophages; on tumo...
Alternative Titles
Full title
369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c917f69f84ea4a2c8f0fd765dfdecead
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c917f69f84ea4a2c8f0fd765dfdecead
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2021-SITC2021.369
